Carlsmed to Go Public in $101 Million Bid to Scale 3D Printed Spine Implants

Carlsmed is preparing to go public. The med-tech company, based in Carlsbad, California, plans to offer 6.7 million shares at a price range of $14 to $16 per share, which could raise $101 million. Carlsmed will trade on the Nasdaq under the ticker symbol “CARL.”

Founded in 2018, Carlsmed has grown in the competitive med-tech space. Over the 12 months ending March 31, 2025, the company booked $32 million in revenue, pointing to a momentum in personalized spine surgery. To build on that progress, Carlsmed is now preparing to go public. BofA Securities, Goldman Sachs, and Piper Sandler are leading the initial public offering (IPO), with Truist and BTIG as co-underwriters. This move comes as Carlsmed looks to accelerate its growth and bring its personalized spinal surgery solutions to more patients across the country.

Carlsmed has developed a technology called aprevo, which combines artificial intelligence (AI) and 3D printing to create custom titanium implants for spinal fusion surgeries. Instead of using generic, off-the-shelf implants, many surgeons are turning to Carlsmed for personalized implants designed specifically for each patient.

The process starts with a CT scan of the patient’s spine, which is uploaded to Carlsmed’s planning platform. Its software analyzes the data and designs a unique implant based on the patient’s anatomy. The design is reviewed and approved by the surgeon, then 3D printed in titanium, sterilized, and shipped, ready for use in surgery. The whole process takes less than 10 days.

The results have been promising, with over 500 patients receiving these implants. Most achieved strong bone-to-implant contact, known as graft contact, which is essential for successful spinal fusion. What’s more, the revision rate has been under 2%, meaning very few patients required a second surgery.

Recognized by the U.S. Food and Drug Administration (FDA) as a promising innovation, aprevo has been cleared for use in both lumbar and cervical spine procedures. It was also granted Breakthrough Device designation, a status reserved for technologies that may offer important advantages over existing treatments for serious or debilitating conditions. Between 2015 (when the program began) and 2024, the FDA had granted over 1,000 Breakthrough Device designations across all medical specialties.

This designation shows that aprevo could make a real difference for patients. It also gives Carlsmed a faster and smoother path to market, with priority review and extra support from the FDA. Since only a small number of devices get this status each year, it’s a strong vote of confidence in the technology.

In March 2024, Carlsmed raised $52.5 million in a Series C funding round, bringing its total private funding to roughly $110 million. The funds were used to expand its digital production line, allowing the company to quickly produce and ship custom implants at scale. Now, with its IPO, Carlsmed hopes to expand further, continuing to roll out cervical implants and collect more clinical data through its COMPASS registry.

According to Renaissance Capital, “insiders intend to purchase $31 million worth of shares in the offering, that’s 31% of the deal. At the midpoint of the proposed range, Carlsmed would command a fully diluted market value of $430 million.”

Carlsmed is a strong example of how 3D printing, AI, and personalized medicine are coming together in real-world medical applications. From scan to surgery, they use advanced technology to improve patient outcomes and make spine surgery more effective.